No connection

Search Results

INGN vs LFMD

INGN
Inogen, Inc.
BEARISH
Price
$6.33
Market Cap
$172.4M
Sector
Healthcare
AI Confidence
85%
LFMD
LifeMD, Inc.
BEARISH
Price
$3.47
Market Cap
$166.5M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
INGN
--
LFMD
--
Forward P/E
INGN
-20.42
LFMD
7.8
P/B Ratio
INGN
0.9
LFMD
7.0
P/S Ratio
INGN
0.49
LFMD
0.86
EV/EBITDA
INGN
-7.36
LFMD
-20.27

Profitability

Gross Margin
INGN
44.24%
LFMD
85.72%
Operating Margin
INGN
-12.21%
LFMD
-2.34%
Profit Margin
INGN
-6.52%
LFMD
7.4%
ROE
INGN
-12.43%
LFMD
-131.16%
ROA
INGN
-6.35%
LFMD
-6.54%

Growth

Revenue Growth
INGN
2.0%
LFMD
-27.1%
Earnings Growth
INGN
--
LFMD
--

Financial Health

Debt/Equity
INGN
0.09
LFMD
0.27
Current Ratio
INGN
3.12
LFMD
1.25
Quick Ratio
INGN
2.52
LFMD
1.11

Dividends

Dividend Yield
INGN
--
LFMD
--
Payout Ratio
INGN
0.0%
LFMD
0.0%

AI Verdict

INGN BEARISH

INGN exhibits severe operational distress, highlighted by a critical Piotroski F-Score of 1/9, indicating a significant deterioration in financial health. While the company maintains a strong liquidity position with a Current Ratio of 3.12 and very low debt (D/E 0.09), it is unable to translate this into profitability, as evidenced by negative operating margins and stagnant revenue growth of 2%. There is a stark disconnect between the 'Strong Buy' analyst consensus and the fundamental reality of a 5-year price collapse of 88.6%. The stock currently presents as a classic value trap, trading below book value but lacking the growth catalysts necessary for a reversal.

Strengths
Very low leverage (Debt/Equity 0.09)
Strong short-term liquidity (Current Ratio 3.12)
Healthy Gross Margin (44.24%)
Risks
Critical operational failure (Piotroski F-Score 1/9)
Stagnant top-line growth (YoY Revenue Growth 2.00%)
Persistent net losses and negative ROE (-12.43%)
LFMD BEARISH

LFMD exhibits severe financial deterioration, highlighted by a weak Piotroski F-Score of 2/9 and a catastrophic Q/Q revenue decline of 88.98%. While the company maintains a low debt-to-equity ratio, the combination of negative operating margins, a deeply negative ROE (-131.16%), and a 0/4 earnings beat record over the last four quarters indicates a business in crisis. Despite a high analyst target price of $9.88, the fundamental data and technical trend (0/100) suggest a value trap scenario.

Strengths
High gross margins (85.72%)
Low debt-to-equity ratio (0.27)
Reasonable current ratio (1.25)
Risks
Severe revenue collapse (-88.98% Q/Q)
Consistent earnings misses (0/4 beats in last 4 quarters)
Deeply negative Return on Equity (-131.16%)

Compare Another Pair

INGN vs LFMD: Head-to-Head Comparison

This page compares Inogen, Inc. (INGN) and LifeMD, Inc. (LFMD) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile